Technical Data
D1075-02K
DARPP32, phosphorylated (Thr75) (Dopamine and cAMP-regulated Phosphoprotein, Protein phosphatase 1 regulatory subunit 1B, PP1R1B)
Description:
DARPP-32, a dopamine (DA) and cAMP-regulated ~32k phosphoprotein, is associated with dopaminoceptive neurons bearing D-1 receptors in the basal ganglia. The protein inhibits protein phosphatase I when it is phosphorylated on Thr34. In contrast, when DARPP-32 is phosphorylated on Thr75 the protein acts as an inhibitor of PKA. Phosphorylation of DARPP is thought to play a critical role in the regulation of dopaminergic neurotransmission. In addition, the activity of DARPP-32 is also thought to play important roles in the actions of alcohol, caffeine and Prozac

Applications:
Suitable for use in Western Blot and Dot Blot. Other applications not tested.

Recommended Dilution:
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot Store at -20C. Aliquots are stable for at least 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
TypeIsotypeCloneGrade
PabAffinity Purified
SizeStorageShippingSourceHost
100ul-20CBlue IceHumanRabbit
Concentration:
Not determined
Immunogen:
Synthetic phosphopeptide corresponding to amino acids residues surrounding the phospho Thr75 of DARPP-32. The sequence of the immunogen is identical in human and mouse.
Purity:
Purified by immunoaffinity chromatography.
Form
As reported
Specificity:
Specific for the ~34k DARPP-32 phosphorylated at Thr75. Species Crossreactivity: This antibody recognizes human, mouse, and rat forms of the protein. Other species have not been tested.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Svenningsson, P., Tzavara, E.T., Carruthers, R., Rachleff, I., Wattler, S., Nehls, M., McKinzie, D.L., Fienberg, A.A., Nomikos, G.G.and Greengard, P., "Diverse psychotomimetics act through a common signaling pathway," Science, 302 (2003) 1412 - 1415.
2. Lindskog, M., Svenningsson, P., Pozzi, L., Kim, Y., Fienberg, A.A., Bibb, J.A.., Fredholm, B.B., Nairn, A.C., Greengard, P. and Fisone, G., "Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine, Nature (London), 418 (2002) 774 - 778.
3. Maldve, R.E., Zhang, T.A., Ferrani-Kile, K., Schreiber, S.S., Lippmann, M.J., Snyder, G.L., Feinberg, A.A., Leslie, S.W., Gonzales, R.A., and Morrisett, R.A., "DARPP-32 and the regulation of the ethanol sensitivity of NMDA receptors in the nucleus accumbens," Nature Neurosci. 5 (2002) 641 - 648.
4. Greengard, P., "The neurobiology of slow synaptic transmission," Science 294 (2001) 1024 -1030.
5. Bibb, J.A., Snyder, G.L., Nishi, A., Yan, Z., Meijer, L., Fienberg, A.A., Tsai, L.H., Kwon, Y.T., Girault, J.A., Czernik, A.J., Huganir, R.L., Hemmings, Jr., H.C., Nairn, A.C., and Greengard, P., "Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons, Nature (London) 402 (1999) 669 - 671.
6. Fienberg, A.A., Hiroi, N., Mermelstein, P.G., Song, W., Snyder, G.L., Nishi, A., Cheramy, A. O'Callaghan, J.P., Miller, D.B., Cole, D.G., Corbett, R., Haile, C.N., Cooper, D,C., Onn, S.P., Grace, A.A., Ouimet, C.C., White, F.G., Hyman, S.E., Surmeier, D.G., Girault, J., Nestler, E.J., and Greengard, P., "DARPP-32: regulator of the efficacy of dopaminergic neurotransmission," Science 281 (1998) 838 - 842.
7. Walaas, S.I. and Greengard, P., "DARPP-32, A dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions," J. Neurosci. 4 (1984) 84 -98.
8. Han, J., Han, L., Tiwari, P., Wen, Z., and Zheng, J. Q. (2007) Spatial targeting of type II protein kinase A to filopodia mediates the regulation of growth cone guidance by cAMP, 176, 101-111.